Detalhe da pesquisa
1.
Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes.
Diabetes Obes Metab
; 24(8): 1439-1447, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661378
2.
Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder.
J Urol
; 194(5): 1329-35, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26073872
3.
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.
Diabetes Care
; 44(4): 960-968, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33622669
4.
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.
Schizophr Bull
; 42(2): 335-43, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26071208
5.
Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
J Pain
; 6(1): 21-8, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15629415
6.
Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
Curr Med Res Opin
; 20(6): 911-8, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15200750